Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
Dietary adjustments Food choices during the early weeks of treatment make a significant difference
Wegovy (semaglutide) is a GLP-1 receptor agonist that helps reduce hunger and appetite, allowing you to eat fewer calories, lose weight, and manage your blood sugar levels
Given the rapid increase in semaglutide use and its possible licensing for a range of problems other than obesity and type 2 diabetes, this issue deserves further study, but possible drug side-effects always need to be balanced against likely benefits. Semaglutide under the brand name Wegovy has been prescribed for weight loss on the NHS since 2023
For fajitas, fry peppers, onions, and chicken with spices, then serve with wraps, cheese, and guacamole
The difficulty is that this damage is not always visible